Pharmaceuticals News

SEATTLE, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will...

New Taipei City, Taiwan, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company dedicated to the development...

Eupraxia reached its target enrollment of 120 patients in the Phase 2b placebo-controlled blinded portion of the RESOLVE trialThe Company has a statistical team who are doing periodic reviews of the...

New patent allowances in South Korea, Mexico, New Zealand and the Philippines Further expand IP protection across BPD, ASD, aggression and social withdrawal MADRID and CAMBRIDGE, Mass., Oct. 15,...

LB2501 is an off-the-shelf in vivo CAR-T therapy designed to generate dual-targeting CD19/CD20 CAR-T cells directly within the patient after a single infusion, making it the first known dual-targeting...

Callio Therapeutics wins Best New ADC Drug Developer at the 13th World ADC Awards and presents on dual-payload ADCs at World ADC San Diego 2026.

EIK1006 is a novel androgen receptor (AR) antagonist that is structurally unrelated to currently available lutamide-class antagonists.

Initial Stage 1 data evaluating vensobafusp alfa in IgAN expected by year-end 2026 Announces expansion cohort in patients with FSGS, with first patients anticipated to be dosed in first quarter 2027 ...

TEL AVIV, Israel, Oct. 15, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that it will shift its strategic focus toward Agentic AI-powered...

AN4035, a first-in-class investigational pan-RAS(ON) inhibitor-based ADC, will be evaluated as monotherapy and in combination with cetuximab in the ongoing global Phase I trial Cetuximab will be...